Skip to main content

Table 2 Patient characteristics

From: Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)

Patient-level Characteristics

Total (N = 3,535)

Filgrastim (N = 163)

Pegfilgrastim (N = 3,372)

P-value

Age, mean (SD)

55.2 (10.8)

57.5 (12.6)

55.1 (10.7)

0.018

Female, n (%)

2,788 (78.9)

119 (73.0)

2,669 (79.2)

0.060

Geographic region, n (%)

    

 Northeast

248 (7.0)

26 (16.0)

222 (6.6)

<0.001

 Midwest

970 (27.4)

38 (23.3)

932 (27.6)

0.227

 South

1,778 (50.3)

79 (48.5)

1,699 (50.4)

0.632

 West

539 (15.3)

20 (12.3)

519 (15.4)

0.279

Tumor type, n (%)

    

 Breast cancer

2,054(58.1)

84 (51.5)

1,970 (58.4)

0.082

 Colorectal cancer

46 (1.3)

7 (4.3)

39 (1.2)

<0.001

 Lung cancer

634 (17.9)

30 (18.4)

604 (17.9)

0.873

 Non-Hodgkin’s lymphoma

594 (16.8)

33 (20.3)

561 (16.6)

0.229

 Ovarian cancer

207 (5.9)

9 (5.5)

198 (5.9)

0.852

Baseline Quan-Charlson comorbidity score, mean (SD)*†

4.5 (2.4)

4.4 (2.5)

4.5 (2.4)

0.520

 Score of 2, n (%)

1,131 (32.0)

57 (35.0)

1,074 (31.9)

0.404

 Score of 3–6, n (%)

1,590 (45.0)

61 (37.4)

1,529 (45.3)

0.047

 Score of ≥ 7, n (%)

805 (22.8)

44 (27.0)

761 (22.6)

0.188

History of anemia‡§

3,858 (32.0)

135 (36.2)

3,723 (31.9)

0.078

Count of myelosuppressive chemotherapy agents, mean (SD) for cycles§**

2.13 (0.6)

1.96 (0.6)

2.14 (0.6)

<0.001

Use duration, mean (SD)††

-

4.8 (3.3)

‡‡

-

 1 day, %

-

19.9

-

-

 2 days, %

-

9.9

-

-

 3 days, %

-

14.0

-

-

 4–6days, %

-

23.9

-

-

 ≥ 7 days, %

-

32.3

-

-

  1. * Baseline is the 1-year period preceding the index date (start of chemotherapy course).
  2. Nine patients (0.3%) had a score of 0 (7 patients) or 1 (2 patients).
  3. Anemia occurring in the 120 days prior to the start of each cycle.
  4. § Cycle-level data: 12,056 total cycles of which 373 were filgrastim and 11,683 were pegfilgrastim.
  5. ** Data by cycle, not by patient, as myelosuppressive characteristics were determined at the cycle level.
  6. †† Calculated from cycles in which filgrastim or pegfilgrastim were found on medical claims. Cycles with pharmacy claims for either were not included, as the precise date for the administration of filgrastim or pegfilgrastim could not be determined. These criteria resulted in 322 filgrastim cycles and 11,510 pegfilgrastim cycles.
  7. ‡‡ For pegfilgrastim, there was a mean (SD) of 1.0 (0.15) claims per cycle.